- Home
- RNXT vs SLGL Comparison
RNXT vs SLGL Comparison
Compare RNXT & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNXT | SLGL |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 117.8M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RNXT | SLGL |
|---|---|---|
| Price | $0.95 | $41.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.75 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 197.4K | 15.1K |
| Earning Date | 11-13-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $928,000.00 | ★ $18,970,000.00 |
| Revenue This Year | $2,795.35 | $121.82 |
| Revenue Next Year | $272.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $0.70 | $4.02 |
| 52 Week High | $1.69 | $52.26 |
Technical Indicators
Market Signals| Indicator | RNXT | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 58.15 |
| Support Level | $0.89 | $38.91 |
| Resistance Level | $1.00 | $43.12 |
| Average True Range (ATR) | 0.07 | 3.14 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 59.41 | 76.67 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.